2015
DOI: 10.1039/c4an01806k
|View full text |Cite
|
Sign up to set email alerts
|

Cluster-based comparison of the peptide mass fingerprint obtained by MALDI-TOF mass spectrometry. A case study: long-term stability of rituximab

Abstract: We evaluated the use of the peptide mass fingerprint (PMF) obtained by matrix assisted laser desorption and ionization (MALDI) time-of-flight mass spectrometry (TOF-MS) to track changes in the structure of a protein. The first problem we had to overcome was the inherent complexity of the PMF, which makes it difficult to compare. We dealt with this problem by developing a cluster-based comparison algorithm which takes into account the proportional error made by the mass spectrometer. This procedure involves gro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 25 publications
(31 reference statements)
0
2
0
Order By: Relevance
“…The mass spectra of the all the painting samples, after applying a typical peak detection workflow, 29,30,31 had signals mainly from 500 m/z to 3500 m/z. Figure 2 shows the mass spectra obtained from the digested samples of paint from La Visitación.…”
Section: Resultsmentioning
confidence: 99%
“…The mass spectra of the all the painting samples, after applying a typical peak detection workflow, 29,30,31 had signals mainly from 500 m/z to 3500 m/z. Figure 2 shows the mass spectra obtained from the digested samples of paint from La Visitación.…”
Section: Resultsmentioning
confidence: 99%
“…Here, high‐resolution MS typically reduces noise, and thus, improves the comparability of peptide fingerprints. [ 30 ] However, thanks to the broad sequence coverage, our low‐resolution MS peptide mapping protocol still allowed us to obtain a comprehensive and meaningful overall picture of severe chemical instabilities for pertuzumab.…”
Section: Discussionmentioning
confidence: 99%